Clinical Trials Logo

High Risk Prostate Cancer clinical trials

View clinical trials related to High Risk Prostate Cancer.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05223582 Active, not recruiting - Neoadjuvant Therapy Clinical Trials

Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST Trial

Start date: May 1, 2021
Phase: Phase 2
Study type: Interventional

The aim of this study is to evaluate the safety and efficacy of fluzoparib combined with abiraterone in neoadjuvant treatment of patients with high-risk locoregional prostate cancer. Dr. Yao Zhu from Fudan University Shanghai Cancer Center is the co-leading PI of this study.

NCT ID: NCT04236752 Active, not recruiting - Clinical trials for HIGH RISK PROSTATE CANCER

Stereotactic Pelvic Brachytherapy With HDR Boost for Dose Escalation in High Tier Intermediate and High Risk Prostate ca

SPARE
Start date: September 29, 2014
Phase: N/A
Study type: Interventional

HDR brachytherapy in conjunction with pelvic SABR in high tier intermediate and high risk prostate cancer patients can provide a safe and effective means of radiotherapy dose escalation. Utilizing multiparametric MRI to focally boost the dominant intraprostatic lesion during HDR brachytherapy is safe and feasible.

NCT ID: NCT03340272 Active, not recruiting - Clinical trials for Intermediate Risk Prostate Cancer

PROspective Multicenter Observational Study on Elective Pelvic Nodes Irradiation.

PRO-EPI
Start date: February 21, 2017
Phase:
Study type: Observational [Patient Registry]

The general aim of the study is to describe the use of elective pelvic node irradiation (ENI) in Italy, in patients with intermediate/high/very high-risk prostate cancer patients submitted to adjuvant or radical Radiation Therapy (RT) with or without concomitant Androgen Deprivation hormone Therapy (ADT). The study aims at the definition of survival, toxicity and QoL data in a representative sample of intermediate, high and very high risk prostate cancer patients consecutively recruited in Italian Radiation Oncology Center over two years.